Background: Oral follow-up therapy is problematic in moulds with reduced azolesusceptibility, such as azole-resistant Aspergillus fumigatus infection. Currently, only intravenous liposomal amphotericin B (L-AmB) is advocated by guidelines for the treatment of azole-resistant aspergillosis infections. Preclinical research indicates that high-dose posaconazole (HD-POS) might be a feasible option provided that high drug exposure (ie POS serum through levels >3 mg/L) can be achieved and is safe.
| INTRODUC TI ON
Invasive aspergillosis (IA) in patients with haematological malignancies is associated with a mortality of 20%-30%. 1, 2 Triazole resistance is increasingly reported in different countries through culture-based surveillance studies 3 and is associated with a much higher mortality of 50%-88%. 4, 5 In 2015, a consensus meeting on the management of azole-resistant IA was organised 6 and liposomal amphotericin B (L-AmB) was advocated as the preferred therapy but has obvious toxicity limitations and can only be administered intravenously. Treatment of IA has to be continued for a minimum of 6-12 weeks but occasionally much longer. 7 Other treatment options are therefore urgently needed. Phase II studies on new antifungals are just about to start and subsequent phase III studies typically take 3 or 4 years to complete. Therefore, these drugs will not provide a short term solution. Targeting high-exposure posaconazole (POS) may be a potential oral step-down treatment option for azole-resistant IA and other difficult-to-treat mould infections.
Posaconazole is approved in patients with haematological malignancies both for prophylaxis and treatment of refractory IA or when intolerance to first-line agents occurs. 8, 9 The agent is available as oral suspension, a delayed-release tablet and an intravenous formulation. Oral absorption of POS oral suspension is affected by food and gastric pH. In contrast, POS tablets contain the active drug mixed with a pH-sensitive polymer 10 and this polymer releases the drug in the intestines, causing threefold increased exposures compared to POS oral suspension. 11 Therapeutic drug monitoring (TDM) has been widely implemented to assess therapeutic efficacy of POS oral suspension but its usefulness is in a state of flux following the introduction of the new POS formulations specifically in the setting of prophylaxis. [12] [13] [14] Current guidelines recommend a Ctrough concentration of ≥0.7 mg/L for prophylaxis and >1.0 mg/L for primary and >1.25 mg/L for salvage therapy, 15 although these concentrations were determined independent of the susceptibility of the infecting pathogen. 13 These targets have been derived for susceptible pathogens and are not valid for pathogens with attenuated susceptibilities. A different approach is needed to optimise treatment in case of reduced susceptibility.
Preclinical research indicates that high-dose posaconazole (HD-POS) might be a feasible option provided that high drug exposure (ie POS serum through levels >3 mg/L) can be achieved and is safe. Hence, we argued that oral high-dose treatment strategies might be feasible to treat pathogens with relatively low MICs/MICs just above the clinical breakpoint (low-resistant). Human data on the treatment of pathogens with reduced susceptibility as well as safety of POS Ctrough concentrations of >3 mg/L are sparse.
Here, we review the evidence supporting the use of HD-POS and describe our experience on safety and efficacy in 16 patients. In addition, we describe the adverse events (AE) observed in 25 patients with POS concentrations at the higher end of the population distribution during treatment with the licensed dose.
| PATIENTS/ME THODS
We set out to explore safety of HD-POS and retrospectively collected clinical and laboratory data of patients from 2 Dutch academic medical centres (Erasmus University Medical Centre, was used to determine for the assessment of causality of potential AE with POS. This is a questionnaire for determining a potential likelihood that an adverse drug reaction is actually linked to a drug.
Probability is assigned using a scoring system with the following possible results: definite, probable, possible of doubtful. 16 Medians and 25th to 75th inter-quartile ranges were used for statistic descriptions. This type of research does not fall under the Dutch law of research on human subjects. However, to safeguard the privacy of the patients, the data were stored anonymously after data extraction.
| RE SULTS

| Group 1
Sixteen patients were treated intentionally with HD-POS for 
| Efficacy
Of the 7 patients with azole-resistant IA treated with HD-POS, 4
survived while 3 died from their underlying disease but unrelated to the IA. In two patients, HD-POS was used as salvage therapy.
One patient with IA caused by Aspergillus terreus was treated with HD-POS because serum galactomannan levels increased under conventional dosage which is a predictor of poor outcome ( Table 2 ). All patients with mucormycosis survived. Posaconazole was given to 18 and 7 patients for prophylaxis and treatment, respectively. All observed AEs are described in Table 3 . induced heart failure, hypertension and hypokalaemia was described with low renin and aldosterone levels. The inhibition of the enzyme 11-beta-hydroxysteroid dehydrogenase 2 is suggested as the potential mechanism causing apparent mineralocorticoid excess. [18] [19] [20] This enzyme is homeostatic regulator and damps mineralocorticoid activity by converting cortisol to cortisone.
| Group 2
The AE of HD-POS observed in this study are in line with previous reports of AE due to POS. A phase III study assessing PK and safety of POS tablet demonstrated that nausea and diarrhoea were the most common treatment-related AEs leading to POS discontinuation in 2% and 1%, respectively. 21 
Rash 3
Note: Digits refer to the number of patients in whom these AEs have been documented.
Refractory shock, rapidly fatal. Distributive shock most likely according to treating physician.
These grade 3 or 4 AE were considered at least possible related to POS. prolongation was observed and the median steady-state concentration was 2.04 mg/L. 23 In a single-centre study, 343 courses of POS prophylaxis (IV or tablet) were assessed for safety and effectiveness.
20% of these patients developed liver injury, mostly hyperbilirubinemia but this is often multifactorial. More importantly, grade 3-4 elevations in hepatic enzymes were only observed in 2% of the patients without pre-existing liver injury with mostly spontaneous resolution despite treatment continuation. 24 Thus, in the current literature, information about the toxicity of high POS serum concentrations is limited but no increase in the number of AEs was observed in patients with higher than average serum concentrations. as POS exposure is sufficiently high. 29, 30 Based on these experiments, the required POS exposure (area under the concentration time curve (AUC)) in patients can be calculated for isolates with an increased MIC. The probability of target attainment for treatment of IA using standard dosing of POS tablet is estimated to be ~80%
| Azole-resistant IA
for isolates with POS-MIC of 0.25 mg/L and >90% for isolates with a POS-MIC of 0.125 mg/L. 28 The probability of target attainment for a POS-MIC of 0.5 mg/L was 24% and for a POS-MIC ≥0.5 mg/L it was 0%.
As determination of the AUC requires multiple sampling moments, and this AUC is linear correlated to Ctrough concentrations, quite often the Ctrough concentrations are used in daily practice as surrogate markers. 13, 28 Monte Carlo simulations estimated that the POS Ctrough concentrations needed to be 1.44-1.55 mg/L for isolates with a POS-MIC of 0.25 mg/L and 3.09-3.33 mg/L for isolates with a POS-MIC of 0.5 mg/L. 28 As the aforementioned in vivo experiments indicated that A fumigatus with a POS-MIC of 0.5 mg/L can be treated with elevated POS dosing, we hypothesised that targeting high exposure with HD-POS is an oral step-down treatment option for azole-resistant IA. Although clinical evidence supporting HD-POS has not been described, preclinical animal studies and experience in veterinary medicine provided proof-of-principle for its efficiency. 28,29
| Mucormycosis
Limited in vivo models are available that assess POS for the treatment of mucormycosis. A neutropenic mouse model indicated similar pharmacodynamics for mucormycosis compared to A fumigatus
infections. An AUC/MIC of 87 was needed to treat Rhizopus oryzae infection, which was comparable to the target needed for IA (AUC/ MIC of 76). 31 Efficacy of POS showed a dose-response relationship in another in vivo model of experimental mucormycosis in which a dose of 100 mg/kg/day showed significant reduction of mortality of Lichtheimia corymbifera infection. 32 Similar dose-response relationships were seen for Mucor species and R oryzae. 33, 34 Compared to A fumigatus isolates, the MICs of Mucorales are often higher with a geometric mean CLSI MIC of 0.39 mg/L 35 and an epidemiological cut-off value of 1 mg/L for L corymbifera, R oryzae and R microspores and 4 mg/L for M circinelloides (Figure 1) . 36 Furthermore, the EUCAST MICs for Mucorales are higher than CLSI MICs for most species. 37 Taken into account, the similar target AUC/MIC for Mucorales as A fumigatus, but higher MICs for Mucorales isolates compared to A fumigatus, it seems reasonable to pursue higher than normal POS serum concentrations for the treatment of mucormycosis as long as this is not associated with toxicity. 13 Posaconazole-oral suspension has been used as salvage therapy for mucormycosis with a success rate of approximately 60%-80%. 38 A recently published matched-paired analysis assessed the clinical effectiveness and safety of POS tablets and intravenous formulation in comparison with amphotericin B as first-line treatment and with POS-OS as salvage treatment for invasive mucormycosis. POS tablets and intravenous formulation were effective in terms of treatment response and associated mortality. However, these observations should be interpreted with caution given the small sample size in this study. 43 Clinical data on PK/PD are lacking due to limited susceptibility data from clinical studies. 38 
| Dosing and TDM
The pharmacokinetics of posaconazole tablets are best described by 
| Inhibitory potential of HD-POS
Posaconazole is a strong CYP3A4 inhibitor, and the clinician should therefore also remain vigilant for drug interactions. In our case series, we had two patients with significant interactions. Toxicity of HD-POS in combination with vincristine was seen in a child with ALL, resulting in hepatotoxicity, convulsions and hypertension which might be attributed to the inhibition of CYP3A4 as well as P-gp resulting in increased levels of vincristine. 40 In conclusion, registration of new antifungals with efficacy against azole-resistant A fumigatus is expected to take several more years. Therefore, targeting high serum concentrations of POS using the tablet or IV formulation is, in our point of view, a possible step-down option in patients with azole-resistant IA as long as the POS-MIC is <1 mg/L and for patients treated for mucormycosis with L-AmB. It should only be used when close monitoring for AE is implemented as described above in conjunction with TDM and when the benefits are likely to outweigh the risks.
ACK N OWLED G M ENTS
Part of this work was orally presented at the following conference: 
